Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

JOHNSON & JOHNSON JNJ

Healthcare
Johnson & Johnson, through its subsidiaries, is engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company's primary focus is products related to human health and well-being. It operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the orthopedic, surgery, interventional solutions, cardiovascular intervention, and vision fields. The MedTech segment also offers a commercially available intravascular lithotripsy (IVL) platform for coronary artery disease (CAD) and peripheral artery disease (PAD).


NYSE:JNJ - Post by User

JOHNSON & JOHNSON
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Post by mdaneseon Oct 19, 2021 4:45pm
63 Views
Post# 34024470

Johnson & Johnson Pulls Trigger on Texas Two-Step

Johnson & Johnson Pulls Trigger on Texas Two-StepNew Brunswick, N.J.-based LTL Management LLC filed for bankruptcy protection in the Western District of North Carolina on Oct. 14, with its petition reporting $1 billion to $10 billion in assets and $1 billion to $10 billion in liabilities with funds available for distribution to unsecured creditors. The case has been assigned to Judge J. Craig Whitley (case No. 21-30589).

LTL is a newly created and separate subsidiary of Johnson & Johnson established to manage and defend what the debtor calls “a virtual tidal wave of [talc-related] claims during the last five years.” Read the full analysis here: https://reorg.com/case-summary-johnson-johnson-pulls-trigger-on-texas-two-step-bankruptcy-for-talc-liability-ltl-management-enters-bankruptcy-supported-by-proposed-2b-fund-substantially-in-excess-of-a/
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities